An Educational Opportunity for Clinicians Specializing in the Treatment of
Acute Coronary Syndrome (ACS)



Deepak L. Bhatt, MD, MPH
Executive Director, Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart and Vascular Center
Professor of Medicine
Harvard Medical School
Boston, MA


The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. Conflict resolution must occur prior to the CME/CE activity. ACHL also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.

This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion. The provider’s documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME guidelines.

The following disclosure information has been provided.


Deepak L. Bhatt, MD, MPH (Chair) Type of financial relationships:
Advisory Board:Regado Biosciences
Research Grants:Amarin, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai, Ethicon, Medtronic, Roche, Sanofi Aventis, and The Medicines Company
Discussion of Off-Label, Investigational, or Experimental Drug Use: Antiplatelet therapy – aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor

Staff and Reviewer

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.